Literature DB >> 19164499

Psychiatrists' attitude towards and knowledge of clozapine treatment.

J Nielsen1, M Dahm, H Lublin, D Taylor.   

Abstract

Clozapine is, in most countries, underutilized and the initiation of clozapine is often delayed. The purpose of this study is to investigate the reasons for the delay and the underutilization of clozapine. One hundred psychiatrists were interviewed by phone. The interview was a structured interview with questions regarding attitude to, knowledge of and experiences with clozapine. Forty-eight (48%) psychiatrists had treatment responsibility of fewer than five patients treated with clozapine and 31 of the interviewed psychiatrists (31%) had started clozapine within the last 3 months. Seven psychiatrists (7%) had never prescribed clozapine despite the fact that they had been working more than five years in general psychiatry. Sixty-four psychiatrists (64%) would rather combine two antipsychotics than use clozapine. Sixty-six psychiatrists (66%) believed that patients treated with clozapine were less satisfied with their treatment when compared with those treated with other atypical antipsychotics. Many psychiatrists are reluctant to use clozapine and this might be due to less experience and knowledge of clozapine. A reason for the low awareness of clozapine's properties might be that clozapine is now a generic drug, and therefore, the marketing and education in using the drug is sparse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164499     DOI: 10.1177/0269881108100320

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  53 in total

1.  Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.

Authors:  Senan Maher; Aoife Cunningham; Niamh O'Callaghan; Fintan Byrne; Colm Mc Donald; Shane McInerney; Brian Hallahan
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-30

2.  Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Authors:  Amanda J Wheeler; Celia L Feetam; Jeff Harrison
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 3.  Assessing QT interval prolongation and its associated risks with antipsychotics.

Authors:  Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

4.  Antipsychotic Polypharmacy.

Authors:  Adriana Foster; Jordanne King
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

5.  Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

Authors:  Britta Galling; Alexandra Roldán; Katsuhiko Hagi; Liz Rietschel; Frozan Walyzada; Wei Zheng; Xiao-Lan Cao; Yu-Tao Xiang; Mathias Zink; John M Kane; Jimmi Nielsen; Stefan Leucht; Christoph U Correll
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

6.  Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia.

Authors:  Charles M Richardson; Erica A Davis; Gopal R Vyas; Bethany A DiPaula; Robert P McMahon; Deanna L Kelly
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

7.  Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Authors:  Jimmi Nielsen; Søren Skadhede; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-06-02       Impact factor: 7.853

8.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

9.  Factors associated with non evidence-based prescribing of antipsychotics.

Authors:  Anne Connolly; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

Review 10.  Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Authors:  Nitin Toteja; Juan A Gallego; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.